Credit Suisse’s Flexion Therapeutics, Inc. FLXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-53,368
| Closed | -$325K | – | 4767 |
|
|
2021
Q3 | $325K | Buy |
53,368
+6,051
| +13% | +$37.7K | ﹤0.01% | 4053 |
|
|
2021
Q2 | $389K | Sell |
47,317
-6,872
| -13% | -$58.4K | ﹤0.01% | 3987 |
|
|
2021
Q1 | $485K | Sell |
54,189
-47,263
| -47% | -$542K | ﹤0.01% | 3786 |
|
|
2020
Q4 | $1.17M | Sell |
101,452
-13,580
| -12% | -$158K | ﹤0.01% | 3232 |
|
|
2020
Q3 | $1.2M | Sell |
115,032
-17,931
| -13% | -$220K | ﹤0.01% | 2799 |
|
|
2020
Q2 | $1.75M | Buy |
132,963
+89,105
| +203% | +$924K | ﹤0.01% | 2492 |
|
|
2020
Q1 | $345K | Sell |
43,858
-9,584
| -18% | -$144K | ﹤0.01% | 3336 |
|
|
2019
Q4 | $1.11M | Sell |
53,442
-38,689
| -42% | -$652K | ﹤0.01% | 3048 |
|
|
2019
Q3 | $1.26M | Buy |
92,131
+17,297
| +23% | +$205K | ﹤0.01% | 2840 |
|
|
2019
Q2 | $920K | Buy |
74,834
+43,550
| +139% | +$502K | ﹤0.01% | 2998 |
|
|
2019
Q1 | $391K | Buy |
31,284
+4,048
| +15% | +$54.1K | ﹤0.01% | 3469 |
|
|
2018
Q4 | $308K | Buy |
27,236
+4,182
| +18% | +$65.6K | ﹤0.01% | 3503 |
|
|
2018
Q3 | $431K | Sell |
23,054
-8,457
| -27% | -$194K | ﹤0.01% | 3380 |
|
|
2018
Q2 | $814K | Sell |
31,511
-1,631
| -5% | -$42.3K | ﹤0.01% | 3164 |
|
|
2018
Q1 | $743K | Buy |
33,142
+1,029
| +3% | +$25.1K | ﹤0.01% | 3153 |
|
|
2017
Q4 | $804K | Sell |
32,113
-2,495
| -7% | -$61.1K | ﹤0.01% | 3150 |
|
|
2017
Q3 | $837K | Sell |
34,608
-3,191
| -8% | -$75K | ﹤0.01% | 3225 |
|
|
2017
Q2 | $765K | Sell |
37,799
-378
| -1% | -$7.87K | ﹤0.01% | 2866 |
|
|
2017
Q1 | $1.03M | Buy |
38,177
+19,948
| +109% | +$407K | ﹤0.01% | 2846 |
|
|
2016
Q4 | $347K | Buy |
18,229
+3,465
| +23% | +$66.2K | ﹤0.01% | 3595 |
|
|
2016
Q3 | $289K | Sell |
14,764
-2,906
| -16% | -$49.2K | ﹤0.01% | 3668 |
|
|
2016
Q2 | $264K | Buy |
17,670
+4,814
| +37% | +$60.5K | ﹤0.01% | 3749 |
|
|
2016
Q1 | $118K | Buy |
+12,856
| New | +$156K | ﹤0.01% | 3802 |
|
|
2015
Q4 | – | Sell |
-10,226
| Closed | -$152K | – | 4412 |
|
|
2015
Q3 | $152K | Sell |
10,226
-2,656
| -21% | -$62.3K | ﹤0.01% | 4016 |
|
|
2015
Q2 | $282K | Buy |
+12,882
| New | +$260K | ﹤0.01% | 4050 |
|
|
2014
Q2 | – | Sell |
-10,074
| Closed | -$166K | – | 4856 |
|
|
2014
Q1 | $166K | Buy |
+10,074
| New | +$174K | ﹤0.01% | 4412 |
|
Credit Suisse's FLXN Position: Q4 2021 in Review
Credit Suisse sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 53,368 shares — an estimated $325K sold.
Credit Suisse first reported a position in FLXN in Q1 2014 and held it in 26 quarters. The position peaked at $1.75M in Q2 2020. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.
- Credit Suisse reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
- Credit Suisse sold 53,368 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $325K.
- Credit Suisse first reported a position in Flexion Therapeutics, Inc. in Q1 2014 and held it in 26 quarters.
- Credit Suisse's Flexion Therapeutics, Inc. position peaked at $1.75M in Q2 2020.
- 1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.
Based on Credit Suisse's 13F filing for Q4 2021, filed 14 Feb 2022.